Erlotinib Study for Myelodysplastic Syndrome (MDS)
Genentech, Inc.
H. Lee Moffitt Cancer Center and Research Institute

      The purpose of this research study is to find out what effects, good and/or bad, erlotinib
      has on the patient and their myelodysplastic syndrome. Erlotinib has been approved by the
      Food and Drug Administration (FDA) to treat non-small cell lung cancer; however, erlotinib
      use in this study is considered investigational as the FDA has not approved it for the
      treatment of myelodysplastic syndrome.
    
Drug